Monoclonal antibodies are developed by identical immune cells, which have a therapeutic use. The crystallized fragments (Fc) protein and glycoengineered antibodies are known as the next generation antibodies. These monoclonal antibodies are immunoglobulin G (IgG) type of molecules, which are attached to a glycan residue on crystallisable fragment. Glycoengineering is the method by which these antibodies are created. They have varied applications for the treatment of diseases such as multiple sclerosis and cancers.

Ask Sample Copy of Research: https://www.coherentmarketinsights.com/insight/request-sample/2626

Global Fc Protein and Glycoengineered Antibodies Market Drivers

Key players in the market are focusing on research and development activities and receiving approvals from regulatory bodies, which are expected to boost the global Fc protein and glycoengineered antibodies market growth over the forecast period.

For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc. began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline are expected to drive the global fc protein and glycoengineered antibodies market growth.

Global Fc Protein and Glycoengineered Antibodies Market Regional Analysis

North America region is expected to dominate in the global fc protein and glycoengineered antibodies market due to factors such as product launches, presence of leading manufacturers (such as F. Hoffmann La-Roche Ltd.), and active research and development in the field. Drugs such as Obinutuzumab (Gazyva), Mogamulizumab (Poteligeo), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi) have been approved in the U.S. in 2013, 2018, 2016, and 2017 respectively.

Europe is expected to witness significant growth in the global Fc protein and glycoengineered antibodies market. Factors such as approval for new drugs is expected to drive the Europe’s Fc protein and glycoengineered antibodies market growth over the forecast period. For instance, in 2018, Kyowa Hakko Kirin Co. Ltd. received an approval from the European Commission to market the Poteligeo antibody in the European market. It is the first biological product that is being directed against chemokine receptor 4 (CCR4), which will be used for the treatment of Sezary syndrome that has been previously treated by systemic therapy. Such new drug approvals are expected to propel Europe Fc protein and glycoengineered antibodies market growth over the forecast period.

Global Fc Protein and Glycoengineered Antibodies Market Key Players

Some of the major players operating in the global Fc protein and glycoengineered antibodies market include Kyowa Hakko Kirin Co. Ltd., Merck KGaA, Boehringer Ingelheim International GmbH, AstraZeneca Plc, Amgen Inc., Genentech Inc., Five Prime Therapeutics Inc., Celldex Therapeutics, Clovis Oncology, and TG Therapeutics, Inc.

Global Fc Protein and Glycoengineered Antibodies Market Taxonomy

The global Fc protein and glycoengineered antibodies market is segmented on the basis of drug, application, and region.

By Drug

• Approved Drugs
- Obinutuzumab (Gazyva)
- Mogamulizumab (Poteligeo)
- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
• Pipeline Drugs
• Ublituximab
• Others

By Application

• Oncology
• Autoimmune Disease
• Others

Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoing-insight/fc-protein-and-glycoengineered-antibodies-market-2626

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]